KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

Biomarin Pharmaceutical (BMRN) Amortization - Deferred Charges: 2013-2018

  • Biomarin Pharmaceutical's Amortization - Deferred Charges rose 13.32% to $1.0 million in Q2 2018 from the same period last year, while for Jun 2018 it was $3.5 million, marking a year-over-year increase of 5.27%. This contributed to the annual value of $3.6 million for FY2018, which is 3.09% down from last year.
  • As of Q2 2018, Biomarin Pharmaceutical's Amortization - Deferred Charges stood at $1.0 million, which was up 13.32% from $886,000 recorded in Q2 2017.
  • Biomarin Pharmaceutical's 5-year Amortization - Deferred Charges high stood at $1.0 million for Q2 2018, and its period low was $823,000 during Q3 2015.
  • In the last 2 years, Biomarin Pharmaceutical's Amortization - Deferred Charges had a median value of $945,000 in 2017 and averaged $945,000.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Amortization - Deferred Charges surged by 1,214.29% in 2014, and later dropped by 0.60% in 2015.
  • Quarterly analysis of 4 years shows Biomarin Pharmaceutical's Amortization - Deferred Charges stood at $827,000 in 2014, then fell by 0.48% to $823,000 in 2015, then reached $886,000 in 2017, then increased by 13.32% to $1.0 million in 2018.
  • Its Amortization - Deferred Charges was $1.0 million in Q2 2018, compared to $886,000 in Q2 2017 and $823,000 in Q4 2015.